MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:08Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 27:		Line 27:
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring = Blood pressure; sedation; alcohol use.		\| monitoring = Blood pressure; sedation; alcohol use.
	\| counseling = '''Avoid alcohol''' — combination causes severe hypotension and syncope. Avoid strong/moderate CYP3A4 inhibitors. Take at bedtime to minimize sedation. Effects on desire emerge over 8 weeks; discontinue if no benefit by then.		\| counseling = '''Avoid alcohol''', combination causes severe hypotension and syncope. Avoid strong/moderate CYP3A4 inhibitors. Take at bedtime to minimize sedation. Effects on desire emerge over 8 weeks; discontinue if no benefit by then.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Bupropion]] (off-label for SSRI-induced sexual side effects)		\| seealso = [[Bupropion]] (off-label for SSRI-induced sexual side effects)

MDElliottMD: Create Flibanserin scaffold

2026-05-15T15:30:22Z

Create Flibanserin scaffold

New page

{{MedTemplate
| generic = Flibanserin
| brand = Addyi
| classes = Multimodal serotonergic; HSDD treatment
| uses = <vote slug="hsdd-use">Hypoactive Sexual Desire Disorder (HSDD)</vote>
| starting_dose = 100 mg at bedtime daily
| preparations = 100 mg tabs
| fda_max = 100 mg/d
| routes = Oral
| onset = Effects accumulate over weeks; assess at 8 weeks
| duration = Continuous daily dosing
| halflife = ~11 h
| bioavailability = ~33%
| pregnancy = Not indicated; pregnancy effects unknown
| legal = Rx-only in US (REMS program)
| mechanism = 5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire.
| intro = Flibanserin is the first FDA-approved medicine for premenopausal generalized acquired hypoactive sexual desire disorder (HSDD), 2015. Dosed at bedtime nightly because of significant CNS depression; effects emerge gradually over weeks. Carries a BLACK BOX warning about hypotension and syncope with alcohol or moderate-to-strong CYP3A4 inhibitors.
| indications =
| dosing =
| effects =
| pk_absorption = Peak in ~45 min.
| pk_distribution = Plasma protein binding ~98%.
| pk_metabolism = Hepatic; CYP3A4 primary, CYP2C19 minor.
| pk_elimination = Fecal and renal as metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure; sedation; alcohol use.
| counseling = '''Avoid alcohol''' — combination causes severe hypotension and syncope. Avoid strong/moderate CYP3A4 inhibitors. Take at bedtime to minimize sedation. Effects on desire emerge over 8 weeks; discontinue if no benefit by then.
| anecdotes =
| seealso = [[Bupropion]] (off-label for SSRI-induced sexual side effects)
| references = <references/>
}}

[[Category:Medicines]]

Flibanserin - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Create Flibanserin scaffold